International Stem Cell Corporation to Present at 65th American Academy of Neurology Annual Meeting

Published: Mar 05, 2013

CARLSBAD, CA--(Marketwire - March 05, 2013) - International Stem Cell Corporation (OTCQB: ISCO) ( a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells announced today that it will present results of pre-clinical studies of Parkinson's disease (PD) at the 65th American Academy of Neurology Annual Meeting at the San Diego Convention Center, San Diego, California on Wednesday, March 20th, 2013.

At the meeting Dr. Ruslan Semechkin, Vice President of Research and Development for ISCO, will present results from efficacy studies of stem cell derived neuronal cells for the treatment of Parkinson's disease. Results and conclusions from both rodent and non-human primate models of the disease will be presented.

The American Academy of Neurology Annual Meeting is one of the world's most important annual events for neurologists and neuroscience professionals and the largest such international meeting of its kind with more than 12,000 attendees at last year's meeting.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (, and stem cell-based skin care products through its subsidiary Lifeline Skin Care ( More information is available at

To receive ongoing corporate communications via email, visit:

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: and


International Stem Cell Corporation
Dr. Simon Craw
Executive Vice President
Phone: 760-940-6383

Dr. Ruslan Semechkin
Vice President, R&D
Phone: 760-940-6383

Investor Relations:
MZ Group
Mark McPartland
Senior Vice President
Phone: 212-301-7130

Back to news